Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
No Longer Available No phase listed Expanded access

A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation

ClinicalTrials.gov ID: NCT00149981

Public ClinicalTrials.gov record NCT00149981. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Facilitated access to everolimus until it is commercially available and reimbursable by appropriate parties

Study identification

NCT ID
NCT00149981
Recruitment status
No Longer Available
Study type
Expanded access
Phase
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Not listed
Completion
Not listed
Last update posted
Sep 9, 2019

United States locations

U.S. sites
68
U.S. states
29
U.S. cities
54
Facility City State ZIP Site status
Novartis Investigative Site Birmingham Alabama 35233 —
Novartis Investigative Site Birmingham Alabama 35294-0006 —
Novartis Investigative Site Mobile Alabama 36617 —
Novartis Investigative Site Los Angeles California 90024 —
Novartis Investigative Site Los Angeles California 90027 —
Novartis Investigative Site Los Angeles California 90048 —
Novartis Investigative Site Los Angeles California 90057 —
Novartis Investigative Site Los Angeles California 90095 —
Novartis Investigative Site San Diego California 92103-8745 —
Novartis Investigative Site San Francisco California 94115 —
Novartis Investigative Site Stanford California 94304 —
Novartis Investigative Site Aurora Colorado 80045 —
Novartis Investigative Site Denver Colorado 80218 —
Novartis Investigative Site New Haven Connecticut 06510 —
Novartis Investigative Site Gainesville Florida 32610-0277 —
Novartis Investigative Site Tampa Florida 33606 —
Novartis Investigative Site Atlanta Georgia 30309 —
Novartis Investigative Site Atlanta Georgia 30322 —
Novartis Investigative Site Augusta Georgia 30912-3140 —
Novartis Investigative Site Chicago Illinois 60612 —
Novartis Investigative Site Chicago Illinois 60637 —
Novartis Investigative Site Maywood Illinois 60153 —
Novartis Investigative Site Des Moines Iowa 50309 —
Novartis Investigative Site Lexington Kentucky 40536-0293 —
Novartis Investigative Site New Orleans Louisiana 70112 —
Novartis Investigative Site New Orleans Louisiana 70121 —
Novartis Investigative Site Shreveport Louisiana 71103 —
Novartis Investigative Site Baltimore Maryland 21287 —
Novartis Investigative Site Boston Massachusetts 02111 —
Novartis Investigative Site Worcester Massachusetts 01655 —
Novartis Investigative Site Ann Arbor Michigan 48109-0331 —
Novartis Investigative Site St Louis Missouri 63104-1314 —
Novartis Investigative Site St Louis Missouri 63110 —
Novartis Investigative Site Omaha Nebraska 68198 —
Novartis Investigative Site Livingston New Jersey 07039 —
Novartis Investigative Site New Brunswick New Jersey 08901 —
Novartis Investigative Site Albany New York 12208 —
Novartis Investigative Site Buffalo New York 14203 —
Novartis Investigative Site New York New York 10032 —
Novartis Investigative Site The Bronx New York 10467 —
Novartis Investigative Site Valhalla New York 10595 —
Novartis Investigative Site Durham North Carolina 27710 —
Novartis Investigative Site Greenville North Carolina 27834 —
Novartis Investigative Site Winston-Salem North Carolina 27157 —
Novartis Investigative Site Fargo North Dakota 58122 —
Novartis Investigative Site Cleveland Ohio 44106-5048 —
Novartis Investigative Site Cleveland Ohio 44195 —
Novartis Investigative Site Columbus Ohio 43205-2696 —
Novartis Investigative Site Columbus Ohio 43210 —
Novartis Investigative Site Philadelphia Pennsylvania 19102 2293 —
Novartis Investigative Site Philadelphia Pennsylvania 19104 —
Novartis Investigative Site Philadelphia Pennsylvania 19140 —
Novartis Investigative Site Providence Rhode Island 02903 —
Novartis Investigative Site Charleston South Carolina 29403 —
Novartis Investigative Site Charleston South Carolina 29425 —
Novartis Investigative Site Nashville Tennessee 37212 —
Novartis Investigative Site Dallas Texas 75246 —
Novartis Investigative Site Galveston Texas 77555-0144 —
Novartis Investigative Site Houston Texas 77030 —
Novartis Investigative Site San Antonio Texas 78229 —
Novartis Investigative Site Murray Utah 84157 —
Novartis Investigative Site Salt Lake City Utah 84132 —
Novartis Investigative Site Charlottesville Virginia 22908 —
Novartis Investigative Site Norfolk Virginia 23507 —
Novartis Investigative Site Richmond Virginia 23284 —
Novartis Investigative Site Charleston West Virginia 25301 —
Novartis Investigative Site Madison Wisconsin 53792 —
Novartis Investigative Site Milwaukee Wisconsin 53215 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 85 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00149981, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 9, 2019 · Synced Nov 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00149981 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →